(PLRX) Pliant Therapeutics - Ratings and Ratios
Fibrosis, Lung, Liver, Skin, Drug
PLRX EPS (Earnings per Share)
PLRX Revenue
Description: PLRX Pliant Therapeutics
Pliant Therapeutics Inc (NASDAQ:PLRX) is a biotechnology company listed on the NASDAQ stock exchange, operating within the biotechnology sub-industry. The companys stock is characterized by high volatility, as indicated by its beta of 1.433, suggesting that its stock price movements are more pronounced compared to the overall market.
From a financial perspective, Pliant Therapeutics has a market capitalization of $101.90 million, indicating a relatively small-cap company. The absence of a price-to-earnings (P/E) ratio, both current and forward, suggests that the company is not profitable, which is not uncommon for biotechnology firms that often invest heavily in research and development. The return on equity (RoE) stands at -67.56%, further highlighting the companys current unprofitability.
Key economic drivers for Pliant Therapeutics include the progress of its pipeline, particularly in the development of treatments for fibrotic diseases and other conditions. Success in clinical trials, regulatory approvals, and eventual commercialization of its products will be crucial for the companys financial health and stock performance. Key performance indicators (KPIs) to watch include the advancement of its clinical programs, partnerships or collaborations that could provide financial support or validation, and the overall landscape of the biotechnology sector.
The stocks technical indicators, such as its moving averages and average true range, suggest a stock with significant price movements. The stock price is currently below its 20-day simple moving average (SMA20) and near its 50-day SMA, indicating a potential area of support. However, it is significantly below its 200-day SMA, a long-term bearish indicator. The average volume indicates a relatively high level of interest in the stock, which can be both a positive and a negative, depending on the direction of the market.
Investors should closely monitor upcoming milestones, such as clinical trial results, regulatory decisions, and any strategic partnerships, as these will likely have a significant impact on the stocks performance. The biotechnology sector is known for its risk and potential for high rewards, making it essential for investors to stay informed and adapt their strategies accordingly.
PLRX Stock Overview
| Market Cap in USD | 105m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2020-06-03 |
PLRX Stock Ratings
| Growth Rating | -83.5% |
| Fundamental | 25.2% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -89.1% |
| Analyst Rating | 3.23 of 5 |
PLRX Dividends
Currently no dividends paidPLRX Growth Ratios
| Growth Correlation 3m | 77.6% |
| Growth Correlation 12m | -74.2% |
| Growth Correlation 5y | -67.2% |
| CAGR 5y | -59.59% |
| CAGR/Max DD 3y | -0.62 |
| CAGR/Mean DD 3y | -1.00 |
| Sharpe Ratio 12m | -0.04 |
| Alpha | 0.20 |
| Beta | 0.388 |
| Volatility | 65.47% |
| Current Volume | 197.2k |
| Average Volume 20d | 592.7k |
| Stop Loss | 1.4 (-8.5%) |
| Signal | -0.34 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-207.0m TTM) > 0 and > 6% of Revenue (6% = 136.2k TTM) |
| FCFTA -0.53 (>2.0%) and ΔFCFTA -28.90pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 10.9k% (prev 26.4k%; Δ -15.5kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.57 (>3.0%) and CFO -169.4m > Net Income -207.0m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 12.99 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (61.4m) change vs 12m ago 1.66% (target <= -2.0% for YES) |
| Gross Margin -12.86% (prev -67.34%; Δ 54.48pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 0.58% (prev 0.33%; Δ 0.25pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -61.36 (EBITDA TTM -201.8m / Interest Expense TTM 3.32m) >= 6 (WARN >= 3) |
Altman Z'' -17.55
| (A) 0.82 = (Total Current Assets 267.4m - Total Current Liabilities 20.6m) / Total Assets 299.8m |
| (B) -2.70 = Retained Earnings (Balance) -809.5m / Total Assets 299.8m |
| warn (B) unusual magnitude: -2.70 — check mapping/units |
| (C) -0.52 = EBIT TTM -203.6m / Avg Total Assets 391.8m |
| (D) -10.15 = Book Value of Equity -809.5m / Total Liabilities 79.7m |
| Total Rating: -17.55 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 25.16
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield data missing |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.14 = 2.49 |
| 5. Debt/Ebitda -0.16 = -2.50 |
| 6. ROIC - WACC (= -71.46)% = -12.50 |
| 7. RoE -73.45% = -2.50 |
| 8. Rev. Trend -20.86% = -1.56 |
| 9. EPS Trend -65.23% = -3.26 |
What is the price of PLRX shares?
Over the past week, the price has changed by -12.57%, over one month by -2.55%, over three months by +12.50% and over the past year by -87.11%.
Is Pliant Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of PLRX is around 1.10 USD . This means that PLRX is currently overvalued and has a potential downside of -28.1%.
Is PLRX a buy, sell or hold?
- Strong Buy: 1
- Buy: 1
- Hold: 11
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the PLRX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 3 | 93.5% |
| Analysts Target Price | 3 | 93.5% |
| ValueRay Target Price | 1.2 | -21.6% |
Last update: 2025-09-05 04:56
PLRX Fundamental Data Overview
CCE Cash And Equivalents = 262.9m USD (Cash And Short Term Investments, last quarter)
P/S = 3071.8201
P/B = 0.477
Beta = 1.433
Revenue TTM = 2.27m USD
EBIT TTM = -203.6m USD
EBITDA TTM = -201.8m USD
Long Term Debt = 30.4m USD (from longTermDebt, last quarter)
Short Term Debt = 1.23m USD (from shortTermDebt, last quarter)
Debt = 31.6m USD (Calculated: Short Term 1.23m + Long Term 30.4m)
Net Debt = -56.8m USD (from netDebt column, last quarter)
Enterprise Value = -126.3m USD (105.0m + Debt 31.6m - CCE 262.9m)
Interest Coverage Ratio = -61.36 (Ebit TTM -203.6m / Interest Expense TTM 3.32m)
FCF Yield = -126.2% (FCF TTM -159.4m / Enterprise Value -126.3m)
FCF Margin = -7020 % (FCF TTM -159.4m / Revenue TTM 2.27m)
Net Margin = -9117 % (Net Income TTM -207.0m / Revenue TTM 2.27m)
Gross Margin = -12.86% ((Revenue TTM 2.27m - Cost of Revenue TTM 2.56m) / Revenue TTM)
Tobins Q-Ratio = 0.16 (Enterprise Value -126.3m / Book Value Of Equity -809.5m)
Interest Expense / Debt = 2.56% (Interest Expense 809.0k / Debt 31.6m)
Taxrate = 21.0% (US default)
NOPAT = -203.6m (EBIT -203.6m, no tax applied on loss)
Current Ratio = 12.99 (Total Current Assets 267.4m / Total Current Liabilities 20.6m)
Debt / Equity = 0.14 (Debt 31.6m / last Quarter total Stockholder Equity 220.1m)
Debt / EBITDA = -0.16 (Net Debt -56.8m / EBITDA -201.8m)
Debt / FCF = -0.20 (Debt 31.6m / FCF TTM -159.4m)
Total Stockholder Equity = 281.8m (last 4 quarters mean)
RoA = -69.03% (Net Income -207.0m, Total Assets 299.8m )
RoE = -73.45% (Net Income TTM -207.0m / Total Stockholder Equity 281.8m)
RoCE = -65.24% (Ebit -203.6m / (Equity 281.8m + L.T.Debt 30.4m))
RoIC = -65.26% (NOPAT -203.6m / Invested Capital 312.0m)
WACC = 6.19% (E(105.0m)/V(136.6m) * Re(7.45%)) + (D(31.6m)/V(136.6m) * Rd(2.56%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 96.97 | Cagr: 2.50%
Discount Rate = 7.45% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -159.4m)
EPS Correlation: -65.23 | EPS CAGR: -6.20% | SUE: -0.50 | # QB: 0
Revenue Correlation: -20.86 | Revenue CAGR: -9.13% | SUE: N/A | # QB: None
Additional Sources for PLRX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle